Mucopolysaccharidosis (MPS) type II (
Hunter's syndrome) is caused by mutations in the
iduronate 2-sulfatase (IDS) fusion
protein. MPS-II affects the brain, and
enzyme replacement therapy is not effective in the brain, because the
enzyme does not cross the blood-brain barrier. To treat mouse models of MPS-II with brain-penetrating IDS, the lysosomal
enzyme was reengineered as an
IgG-IDS fusion
protein. The mature human IDS was fused to the carboxyl terminus of both heavy chains of the chimeric
monoclonal antibody (MAb) against the mouse
transferrin receptor (TfR), and the fusion
protein is designated cTfRMAb-IDS. The purity and identity of the fusion
protein was confirmed by electrophoresis and Western blotting with
antibodies to mouse
IgG and human IDS. The EC₅₀ of binding of the cTfRMAb-IDS fusion
protein to the mouse TfR (0.85 ± 0.15 nM) was comparable to the EC₅₀ of binding of the cTfRMAb (0.78 ± 0.05 nM). The IDS
enzyme activity of the cTfRMAb-IDS fusion
protein was 126 ± 1 nmol · h⁻¹ · μg⁻¹
protein. After
intravenous injection in the mouse, the cTfRMAb-IDS fusion
protein was rapidly removed from plasma and distributed to tissues, including brain and spinal cord. The uptake of the fusion
protein by brain or spinal cord was 1.3 ± 0.1 and 2.2 ± 0.2% injected dose/g, respectively, which is 100-fold greater than the brain uptake of IDS alone. This work shows that a lysosomal
sulfatase can be reengineered as an
IgG-
enzyme fusion
protein that rapidly penetrates the brain after
intravenous administration.